EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity

Ludovico Messineo, Madison Preuss, Ali Azarbarzin, Daniel Vena, Laura Gell, Atqiya Aishah, Neda Esmaeili, Molly Kim, Isabel Burdick, Tom Chen, David White, Scott A Sands und 1 weitere

CHEST · 2025-03

DOI: 10.1016/j.chest.2025.03.013 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CHEST, 2025-03. Verfasst von Ludovico Messineo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA. …. Hauptthemen laut MEDLINE: Atomoxetine Hydrochloride, Adrenergic Uptake Inhibitors, Sleep Apnea, Obstructive, Piperidines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, National Heart Lung and Blood Institute Division of Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: OSA pharmacologic interventions like the noradrenergic muscle stimulant atomoxetine have wake-promoting properties. Pimavanserin, a promising serotonin 2A receptor antagonist, may help to counteract atomoxetine's noradrenergic effects by increasing arousal threshold and possibly reducing OSA severity. RESEARCH QUESTION: What is the effect of the combination of pimavanserin and atomoxetine on apnea-hypopnea index (AHI; primary outcome), arousal index, and nadir oxygen saturation (Spo2; secondary outcomes)? STUDY DESIGN AND METHODS: After baseline polysomnography, 18 participants with OSA (AHI > 15 events/h) took pimavanserin plus atomoxetine (34/80 mg; 34/40 mg for the first 3 days) or placebo for 1 week according to a randomized, crossover, 2-period, double-masked clinical trial. Follow-up polysomnography was performed to provide study outcomes. Safety outcomes, subjective sleep quality, and flow-estimated endotypes (using oronasal pneumotachograph flow) also were explored. RESULTS: Eleven and 7 participants were randomized to atomoxetine plus pimavanserin and placebo first, respectively. The combination reduced AHI by 42% (95% CI, 18%-60%) vs placebo, meeting the primary outcome (P < .001). Absolute AHI reduction was 16.9 events/h (95% CI, 8.1-23.6 events/h) more than placebo. Nadir Spo2 and arousal index also were improved, by 5.0% (95% CI, 1%-8%) and 10.9 events/h (95% CI, 2.4-18.1 events/h) vs placebo. Overnight heart rate was increased (+4.8 beats/min; 95% CI, 1.5-8.1 beats/min), but no other change in subjective sleep quality or next-morning vital signs was evident. No increased risk for side effects was observed for the combination vs placebo. Treatment vs placebo improved pharyngeal collapsibility (+7.9% of stable breathing during sleep; 95% CI, 1.6%-14.1% of stable breathing during sleep), reduced loop gain by 20% (0.15; 95% CI, -0.23 to -0.07), and did not reduce the arousal threshold. INTERPRETATION: Our results indicate that pimavanserin with atomoxetine is a strong pharmacologic therapy candidate for OSA. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT05350215; URL: www. CLINICALTRIALS: gov.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atomoxetine HydrochlorideAdrenergic Uptake InhibitorsSleep Apnea, ObstructivePiperidinesUreaSerotonin 5-HT2 Receptor AntagonistsHumansMaleCross-Over StudiesFemaleDouble-Blind MethodMiddle AgedDrug Therapy, CombinationAdultPolysomnographySeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

OSA alternative treatmentsOSA endotypinghypnoticspharmacotherapy

Substanzen

Atomoxetine HydrochlorideAdrenergic Uptake InhibitorspimavanserinPiperidinesUreaSerotonin 5-HT2 Receptor Antagonists

Autor:innen und Institutionen

  • Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA. Electronic address: ludovico.messineo@yahoo.it.
  • Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA.
  • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA.

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Heart Lung and Blood Institute Division of Intramural Research

Zitieren

APA

Messineo, L., Preuss, M., Azarbarzin, A., Vena, D., Gell, L., Aishah, A., Esmaeili, N., Kim, M., Burdick, I., Chen, T., White, D., Sands, S. A., & Wellman, A. (2025). Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity. CHEST. https://doi.org/10.1016/j.chest.2025.03.013

Vancouver

Messineo L, Preuss M, Azarbarzin A, Vena D, Gell L, Aishah A, et al. Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity. CHEST. 2025. doi:10.1016/j.chest.2025.03.013

BibTeX
@article{Messineo2025,
  author = {Messineo, Ludovico and Preuss, Madison and Azarbarzin, Ali and Vena, Daniel and Gell, Laura and Aishah, Atqiya and Esmaeili, Neda and Kim, Molly and Burdick, Isabel and Chen, Tom and White, David and Sands, Scott A and Wellman, Andrew},
  title = {Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity},
  journal = {CHEST},
  year = {2025},
  doi = {10.1016/j.chest.2025.03.013}
}
Kostenlos starten →